# Carmustine Plus O6-benzylguanine in Treating Patients With Recurrent or Progressive Glioma

> **NCT00005081** · PHASE2 · COMPLETED · sponsor: **Duke University**

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **DRUG:** O6-benzylguanine
- **DRUG:** carmustine

## Key facts

- **NCT ID:** NCT00005081
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-08
- **Primary completion:** 2001-04
- **Final completion:** 2001-04
- **Target enrollment:** — (—)
- **Last updated:** 2014-08-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005081, "Carmustine Plus O6-benzylguanine in Treating Patients With Recurrent or Progressive Glioma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00005081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*